<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755324</url>
  </required_header>
  <id_info>
    <org_study_id>CoHSI1</org_study_id>
    <nct_id>NCT02755324</nct_id>
  </id_info>
  <brief_title>Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding</brief_title>
  <official_title>Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Groups of 3 or 7 volunteers will be exposed to a predetermined number of male Schistosoma&#xD;
      mansoni cercariae until 10 volunteers are found infected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Actual">January 21, 2019</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of grade 3 and 4 adverse events, possibly, probably or definitely related to controlled human Schistosoma mansoni infection with male cercariae.</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of male cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen (CAA).</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average number of weeks until positive serum circulating anodic antigen test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the height of the peak serum circulating anodic antigen concentration in low dose compared with high dose group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the humoral (antibody) response profile by protein and glycan array between infected and uninfected individuals</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in in ex vivo lymphocyte profiles between infected and uninfected individuals</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Schistosomiasis</condition>
  <condition>Schistosoma Mansoni</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>male Schistosoma mansoni cercariae</intervention_name>
    <description>Viable male Schistosoma mansoni cercariae of the Puerto Rican strain</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is aged ≥ 18 and ≤ 45 years and in good health.&#xD;
&#xD;
          2. Subject has adequate understanding of the procedures of the study and agrees to abide&#xD;
             strictly thereby.&#xD;
&#xD;
          3. Subject is able to communicate well with the investigator, is available to attend all&#xD;
             study visits.&#xD;
&#xD;
          4. Subject will remain within Europe (excluding Corsica) during the study period and is&#xD;
             reachable by mobile telephone from week 3 to week 12 of the study period.&#xD;
&#xD;
          5. Subject agrees to refrain from blood donation throughout the study period.&#xD;
&#xD;
          6. For female subjects: subject agrees to use adequate contraception and not to&#xD;
             breastfeed for the duration of study.&#xD;
&#xD;
          7. Subject has signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history, or evidence at screening, of clinically significant symptoms, physical&#xD;
             signs or abnormal laboratory values suggestive of systemic conditions, such as&#xD;
             cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine,&#xD;
             malignant, haematological, infectious, immune-deficient, psychiatric and other&#xD;
             disorders, which could compromise the health of the volunteer during the study or&#xD;
             interfere with the interpretation of the study results. These include, but are not&#xD;
             limited to, any of the following:&#xD;
&#xD;
               -  body weight &lt;50 kg or Body Mass Index (BMI) &lt;18.0 or &gt;30.0 kg/m2 at screening;&#xD;
&#xD;
               -  positive HIV, hepatitis B or hepatitis C screening tests;&#xD;
&#xD;
               -  the use of immune modifying drugs within three months prior to study onset&#xD;
                  (inhaled and topical corticosteroids and oral anti-histamines exempted) or&#xD;
                  expected use of such during the study period;&#xD;
&#xD;
               -  history of malignancy of any organ system (other than localized basal cell&#xD;
                  carcinoma of the skin), treated or untreated, within the past 5 years;&#xD;
&#xD;
               -  any history of treatment for severe psychiatric disease by a psychiatrist in the&#xD;
                  past year;&#xD;
&#xD;
               -  history of drug or alcohol abuse interfering with normal social function in the&#xD;
                  period of one year prior to study onset.&#xD;
&#xD;
               -  Any clinically significant abnormalities (including extended QT interval) on&#xD;
                  electrocardiogram&#xD;
&#xD;
          2. The chronic use of any drug known to interact with praziquantel, or artesunate or&#xD;
             lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon,&#xD;
             dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine,&#xD;
             amitriptyline, clomipramine, class I and III anti-arrythmics, antipsychotics,&#xD;
             antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics,&#xD;
             antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of&#xD;
             drugs with effect on QT interval are excluded from the study.&#xD;
&#xD;
          3. For female subjects: positive urine pregnancy test at screening.&#xD;
&#xD;
          4. Any history of schistosomiasis or treatment for schistosomiasis.&#xD;
&#xD;
          5. Positive serology for schistosomiasis or elevated serum or urine circulating anodic&#xD;
             antigen or positive Schistosoma serology at baseline.&#xD;
&#xD;
          6. Known hypersensitivity to or contra-indications (including co-medication) for use of&#xD;
             praziquantel or, artesunate or lumefantrine.&#xD;
&#xD;
          7. Being an employee or student of the department of parasitology or infectious diseases&#xD;
             of the Leiden University Medical Center.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meta Roestenberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Langenberg MCC, Hoogerwerf MA, Janse JJ, van Lieshout L, Corstjens PLAM, Roestenberg M; CoHSI clinical trial team. Katayama Syndrome Without Schistosoma mansoni Eggs. Ann Intern Med. 2019 May 21;170(10):732-733. doi: 10.7326/L18-0438. Epub 2019 Jan 8.</citation>
    <PMID>30615787</PMID>
  </results_reference>
  <results_reference>
    <citation>Langenberg MCC, Hoogerwerf MA, Koopman JPR, Janse JJ, Kos-van Oosterhoud J, Feijt C, Jochems SP, de Dood CJ, van Schuijlenburg R, Ozir-Fazalalikhan A, Manurung MD, Sartono E, van der Beek MT, Winkel BMF, Verbeek-Menken PH, Stam KA, van Leeuwen FWB, Meij P, van Diepen A, van Lieshout L, van Dam GJ, Corstjens PLAM, Hokke CH, Yazdanbakhsh M, Visser LG, Roestenberg M. A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics. Nat Med. 2020 Mar;26(3):326-332. doi: 10.1038/s41591-020-0759-x. Epub 2020 Feb 17.</citation>
    <PMID>32066978</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Meta Roestenberg</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

